Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Reuters NewMedia - Monday October 29, 2001
Atazanavir, an experimental once-a-day drug in final Phase III clinical trials, belongs to the powerful protease inhibitor class of anti-HIV treatments.
Unlike rival treatments it seems not to cause the metabolic side-effect of highly elevated blood fat levels, Giuseppe Pantaleo of the Hospital de Beaumont in Lausanne, Switzerland, told the 8th European Conference on Clinical Aspects and Treatment of HIV Infection.
"Generally, in regimens that include a protease inhibitor we see a rapid, marked and sustained increase in lipid levels. This does not happen with atazanavir, even at 48 weeks,'' he reported.
Excessive levels of fat in the blood can cause serious heart complications for AIDS patients.
Pantaleo's trial involved 467 patients and tested atazanavir against Viracept, an established protease inhibitor marketed by Pfizer Inc and Roche Holding AG .
Both drugs, when used in a cocktail with other antiretrovirals, were similarly effective in controlling the virus. But those patients on atazanavir experienced a clinically insignificant 5-6 percent increase in cholesterol levels, compared with the 25 percent for Viracept.
"With increasing frequency, physicians who treat people with HIV are confronted with patients with significant lipid disorders. Atazanavir may offer an important new treatment option,'' Pantaleo concluded.
011029
RE011028
Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .